ArticleCancer imaging : the official publication of the International Cancer Imaging Society2025
Differentiating high-grade patterns and predominant subtypes for IASLC grading in invasive pulmonary adenocarcinoma using radiomics and clinical-semantic features.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Temporal radiomics for non-invasive preoperative prediction of pathologic complete response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer.Cancer biology & medicine · 2026Article
- Radiomics to understand pre-treatment tumor biology for resectable non-small cell lung cancer.Frontiers in oncology · 2026Review
- Article
- Development and validation of a CT-based habitat radiomics model for predicting pathological grading in non-small cell lung cancer.Frontiers in medicine · 2026Article
- Differentiation of pulmonary tuberculosis from non-tuberculous solid lung lesions using radiomics and clinical-semantic features on contrast-enhanced CT.Frontiers in medicine · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectivesThe International Association for the Study of Lung Cancer (IASLC) grading system for invasive non-mucinous adenocarcinoma (ADC) incorporates high-grade patterns (HGP) and predominant subtypes (PS). Following the system, this study aimed to explore the feasibility of predicting HGP and PS for IASLC grading. MATERIALS AND
methodsA total of 529 ADCs from patients who underwent radical surgical resection were randomly divided into training and validation datasets in a 7:3 ratio. A two-step model consisting of two submodels was developed for IASLC grading. One submodel assessed whether the HGP exceeded 20% for ADCs, whereas the other distinguished between lepidic and acinar/papillary PS. The predictions from both submodels determined the final IASLC grades. Two variants of this model using either radiomic or clinical-semantic features were created. Additionally, one-step models that directly assessed IASLC grades using clinical-semantic or radiomic features were developed for comparison. The area under the curve (AUC) was used for model evaluation.
resultsThe two-step radiomic model achieved the highest AUC values of 0.95, 0.85, 0.96 for grades 1, 2, 3 among models. The two-step models outperformed the one-step models in predicting grades 2 and 3, with AUCs of 0.89 and 0.96 vs. 0.53 and 0.81 for radiomics, and 0.68 and 0.77 vs. 0.44 and 0.63 for clinical-semantics (p < 0.001). Radiomics models showed better AUCs than clinical-semantic models for grade 3 regardless of model steps.
conclusionsPredicting HGP and PS using radiomics can achieve accurate IASLC grading in ADCs. Such a two-step radiomics model may provide precise preoperative diagnosis, thereby supporting treatment planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.